chitosan has been researched along with atorvastatin in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, R; Basu, AK; Chatterjee, N; Guha, S; Pal, S; Pal, SK; Sarkar, G | 1 |
| Beskonakli, E; Bodur, E; Eroglu, H; Nacar, O; Nemutlu, E; Oner, L; Sargon, MF; Turkoglu, OF | 1 |
| Ahmad, FJ; Akhter, S; Anwar, M; Gahoi, S; Jain, GK; Khar, RK; Mallick, N; Talegaonkar, S; Warsi, MH | 1 |
| Choi, H; Lee, H; Lee, J; Lee, MK | 1 |
| Awad, GA; Kamel, AO; Mekhail, GM; Mortada, ND | 1 |
| Cai, K; Hu, Y; Luo, Z; Xie, D | 1 |
| Bariwal, J; Garg, T; Goyal, AK; Rath, G; Rohilla, R | 1 |
| Abdelaal, MY; El-Helw, AM; Kurakula, M; Sobahi, TR | 1 |
| Ahmed, TA; Kurakula, M | 1 |
| J B, VK; Madhusudhan, B; Ramakrishna, S | 1 |
| Akca, G; Işılay Özdoğan, A; Şenel, S | 1 |
| Akca, G; Comerdov, E; İlarslan, YD; Iskit, AB; Kösemehmetoğlu, K; Kutlu, HB; Özdoğan, AI; Şenel, S | 1 |
| Abdel-Halim, M; Asimakopoulou, A; Hassan, R; Mansour, S; Safy, SE; Tammam, SN; Weiskirchen, R | 1 |
| Arafa, MG; El-Dahan, MS; Girgis, GNS | 1 |
| Anton, N; Batool, F; Benkirane-Jessel, N; Huck, O; Klymchenko, A; Petit, C; Stutz, C; Vandamme, T | 1 |
| Bagheri, F; Darakhshan, S; Mazloomi, S; Shiri Varnamkhasti, B; Tahvilian, R | 1 |
| Biswal, J; Chandra, A; Dash, R; Goel, VK; Mohapatra, S; Prusty, SK; Sharma, T; Yadav, M | 1 |
| Al-Okbi, SY; Ali, O; Aly, AS; Elbakry, HFH; Esmail, RSH; Refaat, D | 1 |
1 trial(s) available for chitosan and atorvastatin
| Article | Year |
|---|---|
Effect of chitosan on lipid levels when administered concurrently with atorvastatin--a placebo controlled study.
Topics: Anticholesteremic Agents; Atorvastatin; Chitosan; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrroles | 2005 |
17 other study(ies) available for chitosan and atorvastatin
| Article | Year |
|---|---|
A quadruped study on chitosan microspheres containing atorvastatin calcium: preparation, characterization, quantification and in-vivo application.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chitosan; Heptanoic Acids; Interleukin-1beta; Interleukin-6; Lipid Peroxidation; Microspheres; Neuroprotective Agents; Pyrroles; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries; Tumor Necrosis Factor-alpha; Wounds and Injuries | 2010 |
Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats.
Topics: Adhesiveness; Administration, Oral; Animals; Atorvastatin; Biological Availability; Chitosan; Chromatography, High Pressure Liquid; Drug Compounding; Drug Stability; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Intestine, Small; Microscopy, Electron, Scanning; Molecular Structure; Nanoconjugates; Particle Size; Pyrroles; Rats; Solubility; Spectroscopy, Fourier Transform Infrared; Surface Properties | 2011 |
Polymer-directed crystallization of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cellulose; Chitosan; Crystallization; Drug Stability; Heptanoic Acids; Models, Molecular; Polyethylene Glycols; Polymers; Powder Diffraction; Pyrroles; Solubility; X-Ray Diffraction | 2012 |
Anticancer effect of atorvastatin nanostructured polymeric micelles based on stearyl-grafted chitosan.
Topics: Antineoplastic Agents; Atorvastatin; Capsules; Chitosan; Delayed-Action Preparations; Drug Carriers; HCT116 Cells; Heptanoic Acids; Humans; MCF-7 Cells; Micelles; Nanostructures; Particle Size; Polymers; Pyrroles; Stearic Acids | 2012 |
Surface engineering of titanium substrates with chitosan-atorvastatin conjugate for reduced inflammation responses and improved cytocompatibility.
Topics: Acid Phosphatase; Animals; Atorvastatin; Biocompatible Materials; Cells, Immobilized; Chitosan; Cytokines; Dogs; Fluorescent Antibody Technique; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; L-Lactate Dehydrogenase; Macrophages; Magnetic Resonance Spectroscopy; Microscopy, Electron, Scanning; Nitric Oxide; Proteins; Pyrroles; Reactive Oxygen Species; Surface Properties; Titanium | 2013 |
Development, optimization and characterization of glycyrrhetinic acid-chitosan nanoparticles of atorvastatin for liver targeting.
Topics: Atorvastatin; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Delivery Systems; Glycyrrhetinic Acid; Hep G2 Cells; Humans; Liver; Nanoparticles; Particle Size | 2016 |
Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy.
Topics: Animals; Atorvastatin; Cations; Chitosan; Drug Stability; Hypolipidemic Agents; Lipids; Male; Nanoparticles; Particle Size; Rats, Wistar | 2015 |
Co-Delivery of Atorvastatin Nanocrystals in PLGA based in situ Gel for Anti-Hyperlipidemic Efficacy.
Topics: Anticholesteremic Agents; Atorvastatin; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Liberation; Gels; Hyperlipidemias; Lactic Acid; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solvents; Surface Properties; X-Ray Diffraction | 2016 |
Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis.
Topics: Administration, Oral; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Chitosan; Curcumin; Delayed-Action Preparations; Diffusion; Drug Combinations; Drug Compounding; Humans; Nanocapsules; Particle Size | 2017 |
Development and in vitro evaluation of chitosan based system for local delivery of atorvastatin for treatment of periodontitis.
Topics: Anti-Inflammatory Agents; Atorvastatin; Chitosan; Cytokines; Drug Delivery Systems; Drug Liberation; Fibroblasts; Gels; Gingiva; Humans; Periodontitis; Viscosity | 2018 |
In vivo evaluation of chitosan based local delivery systems for atorvastatin in treatment of periodontitis.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Chitosan; Cytokines; Drug Delivery Systems; Male; Periodontitis; Rats, Wistar | 2018 |
Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis.
Topics: Actins; Animals; Atorvastatin; Azepines; Carbon Tetrachloride; Chitosan; Disease Models, Animal; Drug Carriers; Drug Evaluation, Preclinical; Drug Synergism; HEK293 Cells; Hepatic Stellate Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Mice; Nanoparticles; Nuclear Proteins; Transcription Factors; Treatment Outcome; Triazoles; Vitamin A | 2019 |
Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Biocompatible Materials; Biological Availability; Chitosan; Drug Carriers; Drug Delivery Systems; Eye Diseases; Gels; Inflammation; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Rabbits | 2020 |
Development of a thermosensitive statin loaded chitosan-based hydrogel promoting bone healing.
Topics: Animals; Atorvastatin; Bone Regeneration; Cells, Cultured; Chitosan; Epithelial Cells; Fibroblasts; Gingiva; Humans; Hydrogels; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mice; Mice, Inbred C57BL; Porphyromonas gingivalis | 2020 |
Dual loading of
Topics: Atorvastatin; Carboxymethylcellulose Sodium; Chitosan; Nanogels; Plant Oils; Polyethylene Glycols; Polyethyleneimine; Staphylococcus aureus | 2021 |
Modeling of chitosan modified PLGA atorvastatin-curcumin conjugate (AT-CU) nanoparticles, overcoming the barriers associated with PLGA: An approach for better management of atherosclerosis.
Topics: Animals; Atherosclerosis; Atorvastatin; Chitosan; Copper; Curcumin; Drug Carriers; Glycols; Mice; Nanoparticles; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer | 2023 |
Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms.
Topics: Animals; Atorvastatin; Chitosan; Diet, High-Fat; Dietary Supplements; Fructose; Insulin Resistance; Metabolic Syndrome; Rats | 2023 |